Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27291313 | 0.83 | MEN1 (0.36) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL24002485 | 0.81 | KDM4E (0.44) | MEN1KMT2AKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL25129049 | 0.81 | KDM4E (0.44) | MEN1KMT2AKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL24864631 | 0.81 | KDM4E (0.37) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL23874295 | 0.79 | KDM4E (0.43) | MEN1KMT2AKDM4ETDP1POLB | |
| SCHEMBL18768950 | 0.76 | ALDH1A1 (0.53) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL22198371 | 0.76 | ALDH1A1 (0.53) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL17853275 | 0.76 | ALDH1A1 (0.53) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL22198424 | 0.76 | ALDH1A1 (0.53) | MEN1KMT2AKDM4ELMNATDP1 | |
| SCHEMBL18769029 | 0.76 | ALDH1A1 (0.53) | MEN1KMT2AKDM4ELMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151890-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| WO-2023280227-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | MEN1 1967/4885KMT2A 2447/4885KDM4E 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.